Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C2599
http://purl.obolibrary.org/obo/NCIT_C2599
|
|---|---|
| Preferred Name | Cintredekin Besudotox |
| Definitions |
A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic immunoregulatory cytokine, linked to a mutated form of pseudomonas exotoxin A; this agent targets and kills tumor cells that express the IL13 receptor (IL13R).The IL13 moiety attaches to the IL13R on the tumor cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic immunoregulatory cytokine, linked to a mutated form of pseudomonas exotoxin A; this agent targets and kills tumor cells that express the IL13 receptor (IL13R).The IL13 moiety attaches to the IL13R on the tumor cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. |
|---|---|
| prefLabel | Cintredekin Besudotox
|
| label | Cintredekin Besudotox
|
| PDQ_Closed_Trial_Search_ID | 38095
|
| code | C2599
|
| Has_Target | |
| prefixIRI | NCIT:C2599
|
| in_subset |
See more
See less
|
| Display_Name | Cintredekin Besudotox
|
| Preferred_Name | Cintredekin Besudotox
|
| FDA_UNII_Code | ZL04JX89M7
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Cintredekin Besudotox
|
| CAS_Registry | 372075-36-0
|
| NSC Number | 722759
|
| NCI_Drug_Dictionary_ID | 38095
|
| Legacy Concept Name | Interleukin-13_PE38QQR_Immunotoxin
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of cancer. It is made by combining interleukin-13 with a toxin from Pseudomonas bacteria. It is a type of recombinant chimeric protein.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38095
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C1434448
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |